Merck Stock Eyes $200 as Key Catalysts Loom

Merck's stock price has surged 19% in the past month to $155.99, outperforming the iShares Biotechnology ETF and placing it among the strongest large-cap pharma runs this year.

The company's near-term prospects hinge on a series of regulatory and clinical events scheduled for September and October, including PDUFA dates for its WINREVAIR and WELIREG treatments.

A successful outcome from these events, combined with a compelling readout from the intismeran autogene vaccine at the ESMO conference in Madrid, could reset consensus estimates and push Merck's stock price toward $200.

However, analysts remain cautious about the company's post-KEYTRUDA growth curve, citing patent cliff concerns and competition from peers such as Pfizer and BioNTech SE.